02256 ABBISKO-B
- 3.440
- +0.020+0.58%
ABBISKO-B News
ABBISKO-B: VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES THE INITIATION OFA CLINICAL STUDY EVALUATING ABSK043IN COMBINATION WITH FURMONERTINIB MESYLATE TABLETS FORTHE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: APPOINTMENT OF JOINT COMPANY SECRETARY ANDWAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND8.17 OF THE LISTING RULES
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB GRANTED ODD BY FDA
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: RESIGNATION OF JOINT COMPANY SECRETARY
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: Next Day Disclosure Return
ABBISKO-B: Notification Letter and Reply Form to Registered Shareholders
ABBISKO-B: Notification Letter and Reply Form to Non-registered Shareholders
ABBISKO-B: FORM OF PROXY FOR THE 2023 ANNUAL GENERAL MEETING
ABBISKO-B: 2023 Environmental, Social and Governance Report
ABBISKO-B: Next Day Disclosure Return
Analysis
Price Target
No Data
